menu
    • menu
    [{"orgOrder":0,"company":"McGill University","sponsor":"LALLEMAND HEALTH SOLUTIONS","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"McGill University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McGill University \/ Lallemand Health Solutions","highestDevelopmentStatusID":"7","companyTruncated":"McGill University \/ Lallemand Health Solutions"},{"orgOrder":0,"company":"McGill University","sponsor":"Clarus","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Enzyme","year":"2021","type":"Licensing Agreement","leadProduct":"Coenzyme Q10","moa":"||Mitochondrial electron transport chain","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"McGill University","amount2":0.040000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"McGill University \/ Clarus","highestDevelopmentStatusID":"1","companyTruncated":"McGill University \/ Clarus"},{"orgOrder":0,"company":"McGill University","sponsor":"BIO-CAT","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Omeprazole","moa":"Potassium-transporting ATPase","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"McGill University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"McGill University \/ BIO-CAT","highestDevelopmentStatusID":"1","companyTruncated":"McGill University \/ BIO-CAT"},{"orgOrder":0,"company":"McGill University","sponsor":"Weizmann Institute of Science | Apotex Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Enoxacin","moa":"Topoisomerase IV | DNA gyrase","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"McGill University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"McGill University \/ Weizmann Institute of Science | Apotex Inc","highestDevelopmentStatusID":"7","companyTruncated":"McGill University \/ Weizmann Institute of Science | Apotex Inc"},{"orgOrder":0,"company":"McGill University","sponsor":"McGill University","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"P3 - Whey","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"McGill University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McGill University \/ McGill University","highestDevelopmentStatusID":"1","companyTruncated":"McGill University \/ McGill University"},{"orgOrder":0,"company":"McGill University","sponsor":"McGill University","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.A.E","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Vitamin D","moa":"Vitamin D receptor","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"McGill University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McGill University \/ McGill University","highestDevelopmentStatusID":"1","companyTruncated":"McGill University \/ McGill University"},{"orgOrder":0,"company":"McGill University","sponsor":"Neurasic Therapeutic","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"McGill University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McGill University \/ McGill University","highestDevelopmentStatusID":"2","companyTruncated":"McGill University \/ McGill University"},{"orgOrder":0,"company":"McGill University","sponsor":"Brain Canada","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Sleep","graph2":"Discovery","graph3":"McGill University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McGill University \/ Brain Canada","highestDevelopmentStatusID":"2","companyTruncated":"McGill University \/ Brain Canada"},{"orgOrder":0,"company":"McGill University","sponsor":"Brain Canada","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2025","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"McGill University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McGill University \/ Brain Canada","highestDevelopmentStatusID":"4","companyTruncated":"McGill University \/ Brain Canada"}]

    Find Clinical Drug Pipeline Developments & Deals by McGill University

    Menu

    McGill University

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            McGill University

                            Canada arrow
                            The MedTech Conference
                            Not Confirmed

                            McGill University

                            Canada arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omeprazole

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : BIO-CAT

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Omeprazole Effect on Postprandial Amino Acids After Mixed Meal

                            Details : Omeprazole is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of unspecified medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 26, 2025

                            Lead Product(s) : Omeprazole

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : BIO-CAT

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            McGill University

                            Canada arrow
                            The MedTech Conference
                            Not Confirmed

                            McGill University

                            Canada arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Brain Canada

                            Deal Size : $0.1 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Brain Cancer Canada Grants $100K to McGill for Pediatric Cancer Research

                            Details : The funding will be used to advance a gene therapy treatment for pediatric high-grade gliomas (pHGG), an aggressive and often fatal group of brain cancers.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 12, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Brain Canada

                            Deal Size : $0.1 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            McGill University

                            Canada arrow
                            The MedTech Conference
                            Not Confirmed

                            McGill University

                            Canada arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Sleep

                            Study Phase : Discovery

                            Sponsor : Brain Canada

                            Deal Size : $1.6 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            McGill, industry, CQDM and Brain Canada collaborate for drug discovery

                            Details : The funding aims to advance the discovery of investigational products that have made significant progress in development and could help treat insomnia and neuropathic pain.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 03, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Sleep

                            Highest Development Status : Discovery

                            Sponsor : Brain Canada

                            Deal Size : $1.6 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            McGill University

                            Canada arrow
                            The MedTech Conference
                            Not Confirmed

                            McGill University

                            Canada arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : P3 - Whey

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Recipient : BIO-CAT

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effects of Microbial Protease Supplementation on Postprandial Plasma Amino Acid Concentrations and Appetite

                            Details : P3 - Whey is a drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 24, 2023

                            Lead Product(s) : P3 - Whey

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Recipient : BIO-CAT

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            McGill University

                            Canada arrow
                            The MedTech Conference
                            Not Confirmed

                            McGill University

                            Canada arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Coenzyme Q10,Caspofungin

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Undisclosed

                            Sponsor : Clarus

                            Deal Size : $40.8 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Clarus Therapeutics and McGill University Announce Exclusive Worldwide Licensing Agreement To Develop and Comm...

                            Details : Under the licensing agreement Clarus will develop and commercialize McGill’s proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans with Coenzyme-Q10 (Ubiquinone).

                            Product Name : Ubiquinone

                            Product Type : Enzyme

                            Upfront Cash : $0.4 million

                            September 16, 2021

                            Lead Product(s) : Coenzyme Q10,Caspofungin

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Undisclosed

                            Sponsor : Clarus

                            Deal Size : $40.8 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            McGill University

                            Canada arrow
                            The MedTech Conference
                            Not Confirmed

                            McGill University

                            Canada arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enoxacin

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Weizmann Institute of Science | Apotex Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Enoxacin for Amyotrophic Lateral Sclerosis (ALS)

                            Details : Enoxacin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Amyotrophic Lateral Sclerosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 12, 2021

                            Lead Product(s) : Enoxacin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Weizmann Institute of Science | Apotex Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            McGill University

                            Canada arrow
                            The MedTech Conference
                            Not Confirmed

                            McGill University

                            Canada arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Probiotic

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I/ Phase II

                            Sponsor : LALLEMAND HEALTH SOLUTIONS

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Probiotics for Enhanced Tissue Carotenoid Status in Premenopausal Women

                            Details : This is a Probiotic drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            August 12, 2020

                            Lead Product(s) : Probiotic

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : LALLEMAND HEALTH SOLUTIONS

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            McGill University

                            Canada arrow
                            The MedTech Conference
                            Not Confirmed

                            McGill University

                            Canada arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vitamin D

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Recipient : Dubai Health Authority

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vitamin D Regulates the Expression of Glucocorticoid Receptors in Blood of Severe Asthmatic Patients

                            Details : Vitamin D is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            June 23, 2020

                            Lead Product(s) : Vitamin D

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Recipient : Dubai Health Authority

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            McGill University

                            Canada arrow
                            The MedTech Conference
                            Not Confirmed

                            McGill University

                            Canada arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Recipient : Neurasic Therapeutic

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Neurasic Therapeutic Launched to Advance Research into Made-in-Canada Therapy for Patients with Chronic Pain

                            Details : Neurasic’s potential drug therapy targets acid-sensing ion channels (ASICs), a gene family of neuronal receptors activated by protons that play a role in multiple neurological disorders.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 04, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Recipient : Neurasic Therapeutic

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth